Why Is Medivation at a Premium on an EV-to-EBITDA Basis?

Why Is Medivation at a Premium on an EV-to-EBITDA Basis?

Medivation is expanding the drug beyond prostate cancer treatment, and it plans to conduct a phase 3 trial for triple negative breast cancer (or TNBC) that would start in the second half of 2016. The company is conducting investigational studies for

(Visited 2 times, 1 visits today)
2
Like
Save

Comments

Write a comment